GT Biopharma, Inc. (GTBP)

GT Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	6.81	3.95	1.08	5.67	8.97
Short-Term Investments	-	-	12.89	10.84	23.01
Cash & Short-Term Investments	6.81	3.95	13.97	16.51	31.98
Cash Growth	72.39%	-71.72%	-15.36%	-48.38%	503.72%
Other Current Assets	0.73	0.28	0.08	0.05	0.19
Total Current Assets	7.54	4.23	14.06	16.56	32.17
Net Property, Plant & Equipment	-	-	0.05	0.17	-
Other Long-Term Assets	-	-	-	0.01	-
Total Assets	8.11	4.23	14.11	16.74	32.17
Accounts Payable	0.75	3.85	4.33	3.14	8.19
Accrued Expenses	1.56	1.8	1.2	1.67	1.9
Short-Term Debt	-	-	-	-	0.03
Current Portion of Leases	-	-	0.06	0.11	-
Other Current Liabilities	-	0.25	1.05	0.02	0.14
Total Current Liabilities	2.32	5.9	6.63	4.94	10.26
Long-Term Leases	-	-	-	0.06	-
Total Long-Term Liabilities	-	-	-	0.06	-
Total Liabilities	2.32	5.9	6.63	5	10.26
Preferred Stock	0	0	0	0	0
Common Stock	0.03	0	0	0.03	1.15
Additional Paid-in Capital	729.66	693.55	689.54	686.17	674.35
Retained Earnings	-723.9	-695.23	-682.07	-674.47	-653.58
Shareholders' Equity	5.79	-1.67	7.48	11.73	21.91
Total Liabilities & Equity	8.11	4.23	14.11	16.74	32.17
Total Debt	0	0	0.06	0.17	0.03
Net Cash (Debt)	6.81	3.95	13.91	16.33	31.95
Net Cash Growth	72.39%	-71.60%	-14.82%	-48.87%	-
Net Cash Per Share	1.24	2.08	10.32	15.38	34.04
Book Value	5.79	-1.67	7.48	11.73	21.91
Book Value Per Share	1.05	-0.88	5.55	11.05	23.35
Tangible Book Value	5.79	-1.67	7.48	11.73	21.91
Tangible Book Value Per Share	1.05	-0.88	5.55	11.05	23.35

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q